Trials / Completed
CompletedNCT00292084
An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection
A Phase II, Multi-Center, Extension Study to Evaluate the Safety and Efficacy of Celgosivir in Combination With Peginterferon Alfa-2b, With or Without Ribavirin, for an Additional 36 Weeks
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- BioWest Therapeutics Inc · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is an extension study of HCV-05-002. The objective of this study is to evaluate the safety and efficacy of celgosivir plus peginterferon alfa-2b, with or without ribavirin, for an additional 36 weeks in patients with chronic hepatitis C genotype 1 infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Celgosivir |
Timeline
- Start date
- 2006-02-01
- Completion
- 2007-10-01
- First posted
- 2006-02-15
- Last updated
- 2008-01-21
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00292084. Inclusion in this directory is not an endorsement.